Abstract
THE FLT3/FLK2 receptor tyrosine kinase is closely related to two receptors, c-Kit and c-Fms, which function with their respective ligands, Kit ligand and macrophage colony-stimulating factor to control differentiation of haematopoietic and non-haematopoietic cells1–5. FLT3/FLK2 is thought to be present on haematopoietic stem cells and found in brain, placenta and testis3–5. We have purified to homogeneity and partially sequenced a soluble form of the FLT3/FLK2 ligand produced by mouse thymic stromal cells. We isolated several mouse and human complementary DNAs that encode polypeptides with identical N termini and different C termini. Some variants contain hydrophobic transmembrane segments, suggesting that processing may be required to release soluble lig-and. The purified ligand enhances the response of mouse stem cells and a primitive human progenitor cell population to other growth factors such as interleukins IL-3 and IL-6 and to granulocyte-macrophage colony-stimulating factor, and also stimulates fetal thymocytes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sherr, C. J. Blood 75, 1–12 (1990).
Witte, O. N. Cell 63, 5–6 (1990).
Rosnet, O., Marchetto, S., deLapeyriere, O. & Birnbaum, D. Oncogene 6, 1641–1650 (1991).
Rosnet, O. et al. Blood 82, 1110–1119 (1993).
Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D. & Lemischka, I. R. Cell 65, 1–20 (1991).
Palacios, R. & Steinmetz, M. Cell 41, 727–734 (1985).
Schlessinger, J. & Ullrich, A. Neuron 9, 383–391 (1991).
Galy, A. H. M., de Waal Malefyt, R., Barcena, A., Mohan-Peterson, S. & Spits, H. Thymus 22, 13–33 (1993).
Bazan, J. F. Cell 65, 9–10 (1991).
Pandit, J., Bohm, A., Jancarik, J., Halenbeck, R., Koths, K. & Kim, S. H. Science 258, 1358–1362 (1992).
Sprang, S. R. & Bazan, J. F. Curr. Opin. struct. Biol. 3, 815–827 (1993).
Godfrey, D. I., Zlotnik, A. & Suda, T. J. Immun. 149, 2281–2285 (1992).
Mosmann, T. R. J. Immunol. Meth. 65, 55–63 (1983).
Maroc, N. et al. Oncogene 8, 909–918 (1991).
McKenzie, A. N. J. et al. Proc. natn. Acad. Sci. U.S.A. 90, 3735–3739 (1993).
Sanger, F., Nicklen, S. & Coulson, A. R. Proc. natn. Acad. Sci. U.S.A. 74, 5463–5467 (1977).
Zurawski, S. M. & Zurawski, G. EMBO J. 11, 3905–3910 (1992).
Zurawski, S. M., Vega, F., Huyghe, B. & Zurawski, G. EMBO J. 12, 2663–2670 (1993).
Spangrude, G. J., Heimfeld, S. & Weissman, I. L. Science 241, 58–62 (1988).
Heimfeld, S., Hudak, S., Weissman, I. L. & Rennick, D. Proc. natn. Acad. Sci. U.S.A. 88, 9902–9906 (1991).
Bárcena, A. et al. Blood (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hannum, C., Culpepper, J., Campbell, D. et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368, 643–648 (1994). https://doi.org/10.1038/368643a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/368643a0
This article is cited by
-
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia
Current Treatment Options in Oncology (2023)
-
FLT3-targeted treatment for acute myeloid leukemia
International Journal of Hematology (2022)
-
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
Leukemia (2020)
-
Aptamer-based search for correlates of plasma and serum water T2: implications for early metabolic dysregulation and metabolic syndrome
Biomarker Research (2018)
-
Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice
Nature Communications (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
